Breakthrough T1D Encouraged by Promising Results of FINE-ONE Phase 3 Clinical Trial Evaluating Finerenone for Chronic Kidney Disease Associated with Type 1 Diabetes

NEW YORK, Nov. 6, 2025 /PRNewswire/ — Results of the Bayer-led Phase 3 FINE-ONE clinical trial, presented at the American Society of Nephrology Kidney Week in Houston, demonstrate that finerenone significantly reduced the urine albumin-to-creatine ratio (UACR) from baseline over six…